['venous thromboembolism', 'cancer']
['apixaban', 'placebo drug']

        Inclusion Criteria:

          -  A newly diagnosed cancer site or progression of the malignant disease after complete
             or partial remission.

          -  Initiating a new course of chemotherapy with a minimum intent of 3 months therapy

          -  A VTE risk stratification score of ≥ 2, according to the scoring method

          -  Age 18 years old or older

          -  Provide written informed consent

        Exclusion Criteria:

          -  Lesions or conditions at increased risk of clinically significant bleeding (eg. active
             peptic ulcer disease)

          -  Objectively confirmed substantial liver insufficiency as defined by clinical
             manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or
             biochemical abnormalities in liver function tests including hypoalbuminemia (< 3.5
             gr/dL), elevated levels of total bilirubin (> 25 umol/L), elevated liver transaminases
             (2 times the upper limit of normal) and/or biochemical diagnosis of biliary tract
             obstruction (elevated levels of gamma-glutamyl transferase and alkaline phosphatase, 3
             times the upper limit of normal). *

          -  Diagnosis of basal cell or squamous cell carcinoma of the skin or acute leukemia or
             myelodysplastic syndrome**

          -  Planned stem cell transplant

          -  Life expectancy less than 6 months

          -  Acute or chronic renal insufficiency with glomerular filtration rate (GFR) < 30 ml/min
             calculated by the Cockroft and Gault formula.

          -  Pregnancy***

          -  Continuous anticoagulation with vitamin K antagonists, low-molecular-weight heparin
             (LMWH), or other oral anticoagulants

          -  Weight < 40 Kg

          -  Platelet count < 50 x 109/L

          -  Known allergies to ingredients contained in apixaban

          -  Use of any contraindicated medications with apixaban
      